Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Sep 20, 2024 | 43.21 | +0.20 |
Cushman & Wakefield | CWK | Sep 20, 2024 | 13.43 | -2.11 |
Custom Truck One Source | CTOS | Sep 20, 2024 | 3.71 | -3.39 |
Customers Bancorp | CUBI | Sep 20, 2024 | 47.70 | -3.68 |
Customers Bancorp E Pref | CUBI-E | Sep 20, 2024 | 25.37 | -0.08 |
Customers Bancorp F Pref | CUBI-F | Sep 20, 2024 | 25.19 | -0.21 |
Cutera | CUTR | Sep 20, 2024 | 0.76 | -1.44 |
CVB Financial | CVBF | Sep 20, 2024 | 18.25 | -1.72 |
CVD Equipment | CVV | Sep 20, 2024 | 3.29 | -1.79 |
CVR Energy | CVI | Sep 20, 2024 | 23.47 | -4.59 |
Cvr Partners LP Unit | UAN | Sep 20, 2024 | 69.95 | -0.57 |
CVRx | CVRX | Sep 20, 2024 | 9.11 | -1.51 |
CVS Health | CVS | Sep 20, 2024 | 57.51 | -1.52 |
CXApp A | CXAI | Sep 20, 2024 | 1.78 | +1.71 |
CyberArk Software | CYBR | Sep 20, 2024 | 280.62 | +3.46 |
Cybin | CYBN | Sep 20, 2024 | 9.18 | +7.24 |
Cyclacel Pharmaceuticals | CYCC | Sep 20, 2024 | 0.98 | -3.92 |
Cyclacel Pharmaceuticals Pref | CYCCP | Sep 20, 2024 | 7.00 | 0.00 |
Cyclerion Therapeutics | CYCN | Sep 20, 2024 | 2.93 | +3.53 |
Cyclo Therapeutics | CYTH | Sep 20, 2024 | 0.71 | +3.70 |
Cyngn | CYN | Sep 20, 2024 | 3.64 | -2.93 |
Cytek Biosciences | CTKB | Sep 20, 2024 | 5.09 | -3.78 |
Cytokinetics | CYTK | Sep 20, 2024 | 53.77 | -3.29 |
Cytomed Therapeutics | GDTC | Sep 20, 2024 | 1.55 | 0.00 |
CytomX Therapeutics | CTMX | Sep 20, 2024 | 1.19 | +1.71 |
Cytosorbents | CTSO | Sep 20, 2024 | 1.55 | +9.15 |
D-MARKET Electronic Services & Trading ADR | HEPS | Sep 20, 2024 | 2.33 | -0.85 |
D-Wave Quantum | QBTS | Sep 20, 2024 | 0.93 | -3.40 |
D.R. Horton | DHI | Sep 20, 2024 | 191.89 | -2.62 |
Dada Nexus ADR | DADA | Sep 20, 2024 | 1.18 | -9.92 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.